Treatment of chronic hepatitis C in intravenous drug users: Guidelines of the German Society of Addiction Medicine;Leitlinien der Deutschen Gesellschaft für Suchtmedizin (DGS e.V.): Therapie der chronischen hepatitis C bei intravenös drogengebrauchern

Suchtmedizin in Forschung und Praxis

Volumn 8, Issue 3, 2006, Pages 129-133

  Backmund, Markus ^h   Hinrichsen, Holger ^f   Rossol, Siegbert ^e   Schütz, Christian ^a   Soyka, Michael ^g   Wedemeyer, Heiner ^b   Reimer, Jens ^c   Schäfer, Martin ^d  

^a UNIVERSITY OF BONN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d KLINIKEN ESSEN MITTE   (Germany)

^e KRANKENHAUS NORDWEST   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g Privatklinik Meiringen ^*  (Switzerland)

^h Klinikum Schwabing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ADDICTION; CHRONIC HEPATITIS; CONFERENCE PAPER; DRUG USE; GERMANY; HEPATITIS C; HUMAN; PRACTICE GUIDELINE; TREATMENT CONTRAINDICATION; TUBERCULOSIS;

EID: 33750528938     PISSN: 14375567     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Backmund M, Meyer K, von Zielonka M, Eichenlaub D (2001): Treatment of hepatitis C infection in injection drug users. Hepatology 34, 188-193
2. Backmund M, Gölz J, Kaiser S, Reimer J, Sarrazin C, Wedemeyer H, Marcus U, Schaade L (2003): Empfehlungen zur HCV-Therapie bei i.v. Drogengebrauchern. Erarbeitet auf dem von BMGS und RKI organisierten Expertentreffen am 5.9.2003 in Berlin. Suchtmed 5, 245-247
3. Backmund M, Meyer K, Edlin B (2004): Infrequent Reinfection after Successful Treatment for Hepatitis C Virus Infection in Injection Drug Users. Clin Infect Dis 39, 1540-1543
4. Broers B, Morabia A, Hirschel B (1994): A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med 154, 1121-1127
5. EASL (1999): EASL Consensus Statement - International Consensus Conference on Hepatitis C. J Hepatol 30, 956-961
6. Harrison K, Vlahov D, Jones K, Charron K, Clements ML (1995): Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. J Acquir Immune Defic Syndr Hum Retrovirol 10, 386-390
7. Mezzelani P, Venturini L, Turrina G, Lugoboni F, DesJarlais DC (1991): High compliance with a hepatitis B virus vaccination program among intravenous drug users. J Infect Dis 163, 923
8. National Institutes of Health (1997): Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology 26 Suppl., 71S-77S
9. National Institutes of Health (2002): Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology 36 Suppl., 3S-20S
10. Pilote L, Tulsky JP, Zolopa AR, Hanh JA, Schecter GF, Moss AR (1996): Tuberculosis prophylaxis in the homeless. A trial to improve adherence to referral. Arch Intern Med 156, 161-165
11. Samet JH, Libman H, Steger KA, et al. (1992): Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med 92, 495-484
12. Schäfer M, Schmidt F, Folwaczny C et al. (2003): Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 37, 443-451